Connection
Jawahar Mehta to Angiotensin II Type 1 Receptor Blockers
This is a "connection" page, showing publications Jawahar Mehta has written about Angiotensin II Type 1 Receptor Blockers.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.686 |
|
|
|
-
Chen J, Li D, Schaefer RF, Mehta JL. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis. J Cardiovasc Pharmacol. 2004 Oct; 44(4):446-52.
Score: 0.240
-
Salah HM, Calcaterra G, Mehta JL. Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection. J Cardiovasc Pharmacol Ther. 2020 11; 25(6):503-507.
Score: 0.180
-
Mitra S, Wang X, Khaidakov M, Ding Z, Ayyadevera S, Hearnsberger E, Goyal T, Mehta JL. Aspirin downregulates angiotensin type 1 receptor transcription implications in capillary formation from endothelial cells. J Cardiovasc Pharmacol. 2012 Aug; 60(2):187-92.
Score: 0.103
-
Kang BY, Mehta JL. Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1. J Cardiovasc Pharmacol Ther. 2009 Dec; 14(4):283-91.
Score: 0.084
-
Chen J, Li D, Schaefer R, Mehta JL. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Atherosclerosis. 2006 Feb; 184(2):295-301.
Score: 0.063
-
Chen K, Mehta JL, Li D, Joseph L, Joseph J. Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res. 2004 Dec 10; 95(12):1167-73.
Score: 0.015